David B. Cahn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David B. Cahn has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Alexander Kutikov
Division of Urologic Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania
4 shared publicationsDaniel M. Geynisman
Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
4 shared publicationsMarc C. Smaldone
Division of Urologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA
4 shared publicationsRobert G. Uzzo
Division of Urologic Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania
4 shared publicationsBenjamin T. Ristau
Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA
3 shared publications- Daniel C. Edwards
Department of Urology, Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA
2 shared publications
Latest Publications
- Open Access
- 23 February 2022
- Published by Walter de Gruyter GmbH in Journal of Osteopathic Medicine
- Vol. 122 (6) , 327-328
Transverse colon adenocarcinoma with direct cutaneous extension: complex multidisciplinary surgical management
Article Transverse colon adenocarcinoma with direct cutaneous extension: complex multidisciplinary surgical management was published on February 23, 2022 in the journal Journal of Osteopathic Medicine (volume 0, issue 0).
- 23 February 2022
- Published by Walter de Gruyter GmbH in Journal of Osteopathic Medicine
- Vol. 122 (6) , 327-328
Open AccessTransverse colon adenocarcinoma with direct cutaneous extension: complex multidisciplinary surgical management
Article Transverse colon adenocarcinoma with direct cutaneous extension: complex multidisciplinary surgical management was published on February 23, 2022 in the journal Journal of Osteopathic Medicine (volume 0, issue 0).
Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib‐II renal masses: An analysis of the national cancer data base
BACKGROUND: Partial nephrectomy (PN) is recommended for localized T1a (≤4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC). METHODS: The National Cancer Data Base was queried for patients with T1 and T2 RCC who underwent PN or RN from 2004 to 2014. Trends in surgery were evaluated using Cochran‐Armitage tests. Differences in OS were assessed using adjusted Kaplan‐Meier methods. The effects of procedure on OS were analyzed using propensity score‐based, weighted Cox proportional hazards models. RESULTS: In total, 212,016 patients with T1 and T2 RCC who underwent either RN (59.7%) or PN (40.3%) were included. The use of PN rose from 2004 to 2014 (T1a: from 40.6% to 71.4%; T1b/T2: from 8.4% to 26.5%; P < .01). Adjusted 5‐year OS was longer for patients who underwent PN in both subsets, although effect magnitude was reduced in the T1b/T2 cohort (T1a: 89.6% vs 85.1%; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.70‐0.75; P < .01; T1b/T2: 82.5% vs 80.8%; HR, 0.88; 95% CI, 0.83‐0.94; P = .01). The benefit of PN on OS diminished as age and time from diagnosis increased; no OS improvement was observed in patients age ≥75 years who had T1b/T2 tumors (HR, 0.89; 95% CI, 0.76‐1.06). CONCLUSIONS: Receipt of PN is associated with improved OS in patients with T1a RCC. No procedure‐related differences in OS were observed for patients age ≥75 years who had tumors measuring >4 cm. Decisions to undergo PN for T1b/T2 tumors should be based on individualized risk assessment.
Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib‐II renal masses: An analysis of the national cancer data base
BACKGROUND: Partial nephrectomy (PN) is recommended for localized T1a (≤4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC). METHODS: The National Cancer Data Base was queried for patients with T1 and T2 RCC who underwent PN or RN from 2004 to 2014. Trends in surgery were evaluated using Cochran‐Armitage tests. Differences in OS were assessed using adjusted Kaplan‐Meier methods. The effects of procedure on OS were analyzed using propensity score‐based, weighted Cox proportional hazards models. RESULTS: In total, 212,016 patients with T1 and T2 RCC who underwent either RN (59.7%) or PN (40.3%) were included. The use of PN rose from 2004 to 2014 (T1a: from 40.6% to 71.4%; T1b/T2: from 8.4% to 26.5%; P < .01). Adjusted 5‐year OS was longer for patients who underwent PN in both subsets, although effect magnitude was reduced in the T1b/T2 cohort (T1a: 89.6% vs 85.1%; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.70‐0.75; P < .01; T1b/T2: 82.5% vs 80.8%; HR, 0.88; 95% CI, 0.83‐0.94; P = .01). The benefit of PN on OS diminished as age and time from diagnosis increased; no OS improvement was observed in patients age ≥75 years who had T1b/T2 tumors (HR, 0.89; 95% CI, 0.76‐1.06). CONCLUSIONS: Receipt of PN is associated with improved OS in patients with T1a RCC. No procedure‐related differences in OS were observed for patients age ≥75 years who had tumors measuring >4 cm. Decisions to undergo PN for T1b/T2 tumors should be based on individualized risk assessment.
- 1 April 2018
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (4) , 193-212
Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies
- 1 April 2018
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (4) , 193-212
Use of administrative data for comparative effectiveness research in the treatment of non-prostate genitourinary malignancies
- 1 December 2017
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 35 (12) , 670.e15-670.e21
Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis
- 1 December 2017
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 35 (12) , 670.e15-670.e21
Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis
- Open Access
Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder‐preservation therapy for muscle‐invasive bladder cancer
BACKGROUND: The current study was performed to examine temporal trends and compare overall survival (OS) in patients undergoing radical cystectomy (RC) or bladder‐preservation therapy (BPT) for muscle‐invasive urothelial carcinoma of the bladder.METHODS: The authors reviewed the National Cancer Data Base to identify patients with AJCC stage II to III urothelial carcinoma of the bladder from 2004 through 2013. Patients receiving BPT were stratified as having received any external‐beam radiotherapy (any XRT), definitive XRT (50‐80 grays), and definitive XRT with chemotherapy (CRT). Treatment trends and OS outcomes for the BPT and RC cohorts were evaluated using Cochran‐Armitage tests, unadjusted Kaplan‐Meier curves, adjusted Cox multivariate regression, and propensity score matching, using increasingly stringent selection criteria.RESULTS: A total of 32,300 patients met the inclusion criteria and were treated with RC (22,680 patients) or BPT (9620 patients). Of the patients treated with BPT, 26.4% (2540 patients) and 15.5% (1489 patients), respectively, were treated with definitive XRT and CRT. Improved OS was observed for RC in all groups. After adjustments with more rigorous statistical models controlling for confounders and with more restrictive BPT cohorts, the magnitude of the OS benefit became attenuated on multivariate (any XRT: hazard ratio [HR], 2.115 [95% confidence interval [95% CI], 2.045‐2.188]; definitive XRT: HR, 1.870 [95% CI, 1.773‐1.972]; and CRT: HR, 1.578 [95% CI, 1.474‐1.691]) and propensity score (any XRT: HR, 2.008 [95% CI, 1.871‐2.154]; definitive XRT: HR, 1.606 [95% CI, 1.453‐1.776]; and CRT: HR, 1.406 [95% CI, 1.235‐1.601]) analyses.CONCLUSIONS: In the National Cancer Data Base, receipt of BPT was associated with decreased OS compared with RC in patients with stage II to III urothelial carcinoma. Increasingly stringent definitions of BPT and more rigorous statistical methods adjusting for selection biases attenuated observed survival differences. Cancer 2017;123:4337‐45. © 2017 American Cancer Society.
Open AccessContemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder‐preservation therapy for muscle‐invasive bladder cancer
BACKGROUND: The current study was performed to examine temporal trends and compare overall survival (OS) in patients undergoing radical cystectomy (RC) or bladder‐preservation therapy (BPT) for muscle‐invasive urothelial carcinoma of the bladder.METHODS: The authors reviewed the National Cancer Data Base to identify patients with AJCC stage II to III urothelial carcinoma of the bladder from 2004 through 2013. Patients receiving BPT were stratified as having received any external‐beam radiotherapy (any XRT), definitive XRT (50‐80 grays), and definitive XRT with chemotherapy (CRT). Treatment trends and OS outcomes for the BPT and RC cohorts were evaluated using Cochran‐Armitage tests, unadjusted Kaplan‐Meier curves, adjusted Cox multivariate regression, and propensity score matching, using increasingly stringent selection criteria.RESULTS: A total of 32,300 patients met the inclusion criteria and were treated with RC (22,680 patients) or BPT (9620 patients). Of the patients treated with BPT, 26.4% (2540 patients) and 15.5% (1489 patients), respectively, were treated with definitive XRT and CRT. Improved OS was observed for RC in all groups. After adjustments with more rigorous statistical models controlling for confounders and with more restrictive BPT cohorts, the magnitude of the OS benefit became attenuated on multivariate (any XRT: hazard ratio [HR], 2.115 [95% confidence interval [95% CI], 2.045‐2.188]; definitive XRT: HR, 1.870 [95% CI, 1.773‐1.972]; and CRT: HR, 1.578 [95% CI, 1.474‐1.691]) and propensity score (any XRT: HR, 2.008 [95% CI, 1.871‐2.154]; definitive XRT: HR, 1.606 [95% CI, 1.453‐1.776]; and CRT: HR, 1.406 [95% CI, 1.235‐1.601]) analyses.CONCLUSIONS: In the National Cancer Data Base, receipt of BPT was associated with decreased OS compared with RC in patients with stage II to III urothelial carcinoma. Increasingly stringent definitions of BPT and more rigorous statistical methods adjusting for selection biases attenuated observed survival differences. Cancer 2017;123:4337‐45. © 2017 American Cancer Society.
- Open Access
- 1 July 2015
- Published by Wolters Kluwer Health in Current Urology
- Vol. 8 (2) , 79-83
Predicting Acute Urinary Retention in Patients with Elevated Post-Void Residuals
Objectives: To perform a retrospective analysis evaluating factors that may predict which men with elevated post-void residuals (PVRs) that were at increased risk to develop acute urinary retention (AUR). Methods: We retrospectively analyzed the records of 44 male patients who had 2 consecutive PVRs greater than 100 ml over a 6-month period. Using regression analysis, we evaluated patient's age, PVR volume, prostate specific antigen (PSA) and transrectal ultrasound prostate volume with respect to development of AUR over 24 months. Results: Of the 44 patients, 4 developed AUR. When all factors were considered, prostate volume was determined to be the only that was statistically significant (p = 0.003). A 1-SD increase in prostate volume (12 ml) led to a 19.6% increased risk of developing AUR. There was a strong correlation between PSA and prostate volume (0.787). A regression analysis was then repeated excluding prostate volume. PSA then became a statistically significant predictor of AUR (p = 0.007). A 1-SD increase in PSA (1.377 ng/ml) increased the patients' risk of developing AUR by 12.3%. Conclusion: In men with an elevated PVR, increased transrectal ultrasound prostate volume or PSA may help predict which patients have an elevated risk of developing AUR within the next 24 months. This information may influence which patients need early surgical intervention versus medical therapy.
- 1 July 2015
- Published by Wolters Kluwer Health in Current Urology
- Vol. 8 (2) , 79-83
Open AccessPredicting Acute Urinary Retention in Patients with Elevated Post-Void Residuals
Objectives: To perform a retrospective analysis evaluating factors that may predict which men with elevated post-void residuals (PVRs) that were at increased risk to develop acute urinary retention (AUR). Methods: We retrospectively analyzed the records of 44 male patients who had 2 consecutive PVRs greater than 100 ml over a 6-month period. Using regression analysis, we evaluated patient's age, PVR volume, prostate specific antigen (PSA) and transrectal ultrasound prostate volume with respect to development of AUR over 24 months. Results: Of the 44 patients, 4 developed AUR. When all factors were considered, prostate volume was determined to be the only that was statistically significant (p = 0.003). A 1-SD increase in prostate volume (12 ml) led to a 19.6% increased risk of developing AUR. There was a strong correlation between PSA and prostate volume (0.787). A regression analysis was then repeated excluding prostate volume. PSA then became a statistically significant predictor of AUR (p = 0.007). A 1-SD increase in PSA (1.377 ng/ml) increased the patients' risk of developing AUR by 12.3%. Conclusion: In men with an elevated PVR, increased transrectal ultrasound prostate volume or PSA may help predict which patients have an elevated risk of developing AUR within the next 24 months. This information may influence which patients need early surgical intervention versus medical therapy.
- Open Access
- 1 July 2015
- Published by Wolters Kluwer Health in Current Urology
- Vol. 8 (2) , 101-103
Case Report: Conversion of a Low-Flow to High-Flow Priapism
Priapism is defined as an erection lasting for more than 4 hours and can be grouped into 3 distinct subtypes: ischemic (low-flow), stuttering and non-ischemic (high-flow). Herein, we present an interesting case of conversion from a low-flow to high-flow priapism after a distal shunting procedure. This is a rare phenomenon that has a paucity of documented cases. Diagnosis requires prompt clinical suspicion and confirmatory testing including penile cavernosal blood gases and Doppler ultrasound.
- 1 July 2015
- Published by Wolters Kluwer Health in Current Urology
- Vol. 8 (2) , 101-103
Open AccessCase Report: Conversion of a Low-Flow to High-Flow Priapism
Priapism is defined as an erection lasting for more than 4 hours and can be grouped into 3 distinct subtypes: ischemic (low-flow), stuttering and non-ischemic (high-flow). Herein, we present an interesting case of conversion from a low-flow to high-flow priapism after a distal shunting procedure. This is a rare phenomenon that has a paucity of documented cases. Diagnosis requires prompt clinical suspicion and confirmatory testing including penile cavernosal blood gases and Doppler ultrasound.